Clinical trials / NCT07511361
NCT07511361Phase 2Recruiting

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

Study sponsor: Kardigan, Inc. · KARD

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2026-12Estimated
Enrollment · participants140Estimated
Source updated2026-09-02Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: To assess the effect of tonlamarsen on plasma angiotensinogen (AGT) levels Measure: To assess the systolic blood pressure-lowering effect of tonlamarsen

+ After

Measure: Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptions Measure: Part B: To assess the pharmacodynamic (PD) effect of tonlamarsen on plasma AGT levels

Planned enrollment increased by 40 participants

− Before

100 participants (planned)

+ After

140 participants (planned)

Primary completion date changed

− Before

29 Dec 2026

+ After

Dec 2026

Check registry source

· 1 field changed

Recruitment status changed

− Before

Not yet recruiting

+ After

Recruiting

Check registry source